Research Topics
Species | Andrew H TalalSummaryAffiliation: Cornell University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatmentAndrew H Talal
Center for the Study of Hepatitis C and Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY, USA
J Subst Abuse Treat 44:115-9. 2013..Educational interventions and skill building for staff to confidently engage and support MMTP patients in HCV treatment may be necessary prerequisites for onsite HCV management in MMTPs...
The HCV and HIV coinfected patient: what have we learned about pathophysiology?Andrew H Talal
Weill Medical College of Cornell University, 525 East 68th Street, A354, New York, NY 10021, USA
Curr Gastroenterol Rep 4:15-22. 2002..Also, because several issues concerning HCV are unique to coinfected patients, further research is needed to determine optimal management of HCV in this setting...- Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonrespondersAndrew H Talal
Department of Medicine and the Center for the Study of Hepatitis C, Weill Medical College of Cornell University, New York, NY 10021, USA
Hepatology 43:943-53. 2006..In contrast, pharmacodynamic measurements-namely EC50, the therapeutic quotient, and C(7)/EC50--are different in coinfected SVRs and NRs. These parameters might be useful predictors of treatment outcome during the first month of therapy... - Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIVAndrew H Talal
Department of Medicine, Weill Medical College of Cornell University, New York City, NY, USA
J Acquir Immune Defic Syndr 35:103-13. 2004.... 
Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirinAndrew H Talal
Center for the Study of Hepatitis C, Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
J Acquir Immune Defic Syndr 58:261-8. 2011..Our objective was to compare the effectiveness of intervening with hematologic growth factors versus dose reductions of standard HCV therapy for the management of treatment-induced hematologic disorders...- Opportunistic infections in HIV-infected individuals: hepatitis C virusAndrew Talal
Center for the Study of Hepatitis C and Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
Lancet 360:584-6. 2002 - Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis CMarija Zeremski
Department of Medicine, Division of Gastroenterology and Hepatology, The Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY 10065, USA
Hepatology 48:1440-50. 2008..CONCLUSION: These findings suggest that the CXCR3-associated chemokines, particularly CXCL10, may play an important role in the development of necroinflammation and fibrosis in the liver parenchyma in chronic HCV infection... - HIV/hepatitis C virus-coinfected patients with normal alanine aminotransferase levelsStevan A Gonzalez
Center for the Study of Hepatitis C and Division of Gastroenterology and Hepatology, Department of Medicine, Weill Medical College of Columbia University, 525 East 68th Street, New York, NY 10021, USA
J Acquir Immune Defic Syndr 41:582-9. 2006..The significance of normal alanine aminotransferase (ALT) levels in patients with HIV/hepatitis C virus (HCV) coinfection is not well understood... - Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patientsMarija Zeremski
Division of Gastroenterology and Hepatology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
J Acquir Immune Defic Syndr 45:262-8. 2007..We undertook this study to determine if IP-10 is a marker of treatment outcome in HCV/HIV-coinfected patients... - Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infectionMarija Zeremski
Division of Gastroenterology and Hepatology and Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, USA
J Infect Dis 200:1774-80. 2009..We evaluated the potential of peripheral chemokine levels to discriminate among patients with chronic HCV infection who had different stages of fibrosis... - Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subsetEdgar D Charles
Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, Rockefeller University, 1230 York Avenue, New York, NY 10065, USA
Blood 117:5425-37. 2011..Down-regulation of multiple activation pathways may represent a homeostatic mechanism attenuating otherwise uncontrolled stimulation of circulating HCV-containing immune complexes... - Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patientsP Wilfredo Canchis
Center for the Study of Hepatitis C, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
J Acquir Immune Defic Syndr 37:1125-31. 2004..09 cell/HPF) and monoinfected patients (0.45 +/- 0.08 cell/HPF). In conclusion, HIV coinfection is associated with fewer portal CD4 cells and increased lobular lymphocyte apoptosis that may impact on the natural history of HCV infection... - Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patientsMarie Louise C Vachon
Division of Liver Diseases, Mount Sinai School of Medicine, NY, USA
J Hepatol 54:41-7. 2011.... - Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infectionMarija Zeremski
Center for the Study of Hepatitis C and Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY, USA
J Hepatol 55:545-53. 2011..Characterization of inflammatory mediators, such as chemokines, during acute hepatitis C virus (HCV) infection might shed some light on viral clearance mechanisms... - Identification of substance use and dependence among patients with viral hepatitisColin B Jackson
The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY 10065, USA
Dig Liver Dis 42:650-6. 2010..As drug abuse and addiction have been shown to decrease adherence to treatment of hepatitis C virus (HCV) or HIV, screening for substance use should be standard clinical practice in those undergoing an evaluation for these diseases... - Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virusKristen M Marks
Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
J Infect Dis 192:1943-9. 2005..The prevalence and significance of steatosis in patients coinfected with human immunodeficiency virus (HIV) and HCV are not well characterized... - CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis CMarija Zeremski
Center for the Study of Hepatitis C, Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medical College, New York, USA
J Infect Dis 204:832-6. 2011..0045). Therefore, CXCL10 has potential as a marker of fibrosis progression in African-American HCV-infected patients... - Autoimmune hepatitis in the HIV-infected patient: a therapeutic dilemmaDavid W Wan
Department of Medicine, Weill Medical College of Cornell University, New York, New York 10065, USA
AIDS Patient Care STDS 23:407-13. 2009.... - Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis CRandy S Longman
The Rockefeller University, The Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program, New York, New York, USA
J Infect Dis 192:497-503. 2005..These results are encouraging for DC-based HCV immunotherapy trials... - Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis CDavid Butera
Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, Box 64, 1230 York Ave, New York, NY 10021, USA
Blood 106:1175-82. 2005..This observation has implications for understanding the pathogenesis of HCV infection... - Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemiaEdgar D Charles
Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, Rockefeller University, New York, NY 10021, USA
Blood 111:1344-56. 2008..This study was registered at www.clinicaltrials.gov as NCT00219999... - Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapyKristen M Marks
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
J Acquir Immune Defic Syndr 52:595-9. 2009..Before potent antiretroviral therapy, thrombocytopenia was observed frequently. Little is known about risk factors for or severity and consequences of thrombocytopenia since establishment of highly effective therapy for HIV... - Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysisRositsa B Dimova
Weill Cornell Medical College
Clin Infect Dis 56:806-16. 2013..Treatment of addiction during HCV therapy will likely be important for HCV-infected DUs undergoing treatment with more complex regimens including direct-acting antivirals... - Understanding the pathogenesis and management of hepatitis B/HIV and hepatitis B/hepatitis C virus coinfectionSrinivas Cheruvu
Division of Gastroenterology and Hepatology, Weill Medical College of Cornell University, 525 E 68th Street, Box 319, New York, NY 10065, USA
Clin Liver Dis 11:917-43, ix-x. 2007..In HBV/HCV coinfection HCV usually tends to predominate over HBV. More investigation is needed into the mechanisms by which viral pathogenesis is altered and the optimal treatment modalities for coinfected patients... - IL28B Polymorphism, Pretreatment CXCL10, and HCV RNA Levels Predict Treatment Response in Racially Diverse HIV/HCV Coinfected and HCV Monoinfected PatientsMarija Zeremski
Center for the Study of Hepatitis C and Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY and Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, New York, NY
J Acquir Immune Defic Syndr 63:9-16. 2013..We sought to develop a score to predict sustained virological response (SVR) in racially diverse HIV/hepatitis C virus (HCV)-coinfected and HCV-monoinfected pegylated interferon/ribavirin-treated patients... - Changing treatment paradigms: hepatitis C virus in HIV-infected patientsJaydeep S Kadam
Division of Gastroenterology and Hepatology, Center for the Study of Hepatitis C, Weill Medical College of Cornell University, New York, New York 10021, USA
AIDS Patient Care STDS 21:154-68. 2007..In summary, HCV treatment will likely follow the example forged by HIV. In the near future, combinations of different drugs will likely be used simultaneously to result in durable viral suppression... - Hepatitis C virus infection in USA: an estimate of true prevalenceEric Chak
Department of Medicine, University of California, Sylmar, CA, USA
Liver Int 31:1090-101. 2011..Our most conservative estimates suggest that there are at least 5.2 million persons living with HCV in USA today, approximately 1.9 million of whom were unaccounted for in the NHANES survey... - Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum alpha-fetoproteinP Wilfredo Canchis
Center for the Study of Hepatitis C, Weill Medical College of Cornell University, New York, NY 10021, USA
Liver Int 24:198-203. 2004..0-25.2] cells/HPF; P=0.26). CONCLUSIONS: In patients with chronic HCV infection, HP increases with histologic progression of liver disease, but is impaired in cirrhosis. HP was not increased in patients with elevated serum AFP levels... - Hepatitis C virus in human immunodeficiency virus-infected individuals: an emerging comorbidity with significant implicationsStevan A Gonzalez
Center for the Study of Hepatitis C and Department of Medicine, Weill Medical College of Cornell University, New York, New York10021, USA
Semin Liver Dis 23:149-66. 2003.... - Hepatitis C viral kinetics during treatment of hepatitis C virus/HIV coinfected patientsMarija Zeremski
Division of Gastroenterology and Hepatology, Department of Medicine, and The Center for the Study of Hepatitis C, Weill Medical College of Cornell University, New York, New York, USA
Curr Opin HIV AIDS 2:489-95. 2007..We sought to review data on hepatitis C virus kinetics in hepatitis C virus/HIV coinfected patients and to illustrate how viral kinetics might direct therapeutic decisions in these patients... - Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patientsJianhua Ni
Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10021, USA
J Immunol 170:3429-39. 2003..Instead, factors other than antigenic stimulation may promote the accumulation of peripheral blood B cells with a naive phenotype in a subset of HCV patients... - Dideoxynucleoside analogues should be used cautiously in patients with hepatic steatosisMarija Zeremski
Clin Infect Dis 43:373-6. 2006 - Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirinHarel Dahari
Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, USA
J Hepatol 47:23-30. 2007..We evaluated whether early ribavirin pharmacokinetics differ comparing hepatitis C/human immunodeficiency virus coinfected sustained virological responders and nonresponders... - Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2bKimberly A Powers
Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
Semin Liver Dis 23:13-8. 2003..Models incorporating pharmacokinetics are needed to correctly interpret viral load changes and estimate drug effectiveness in treatment protocols using peginterferon alfa-2b... - Noninvasive markers of hepatic fibrosis: are they ready for prime time in the management of HIV/HCV co-infected patients?Marija Zeremski
J Hepatol 43:2-5. 2005 - Noninjection drug use: an under-appreciated risk factor for hepatitis C virus transmissionAnthony Martinez
Liver Int 28:757-60. 2008 - Presence of functional dendritic cells in patients chronically infected with hepatitis C virusRandy S Longman
Institut Pasteur, 25, rue du Dr Roux, Paris, France 75724
Blood 103:1026-9. 2004..This finding is consistent with clinical and immunologic data that the deficit in the patient's immune repertoire is HCV-specific and suggests that refined models are required for understanding the role of DCs in HCV pathogenesis...
Research Grants
- VIRAL AND IMMUNE RESPONSE TO THERAPY FOR HIV IN THE GALTAndrew Talal; Fiscal Year: 2003..This project amy provide important insights into the amount of time needed to treat HIV- infected individuals and may provide novel approaches by which to monitor therapeutic responses in these individuals. ..